Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol versus tiotropium in severe COPD with prior exacerbations
NL-OMON38156Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol, tiotropium and salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jul 2009; status: active, not recruiting.
02
Drugs
indacateroltiotropiumsalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38156.